Part 1: Long-Term Outcomes of Adjuvant CDK4/6 Inhibitors in HR-Positive/HER2-Negative Early Breast Cancer

We are pleased to present Part 1 of an exclusive podcast, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer.Part 1 of this series provides peer-to-peer physician perspectives on emerging data in the adjuvant treatment of hormone receptor (HR)-positive/HER2-negative early breast cancer.Topics include:The role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in the treatment of early-stage HR-positive/HER2-negative breast cancerLong-term outcomes of CDK4/6 inhibitors including new 7-year data from the monarchE trial and 5-year data from the NATALEE trialDiscussants:Neil M. Iyengar, MDDirector, Survivorship Services, Winship Cancer Institute of Emory UniversityCo-Director, Breast Medical Oncology, Department of Hematology and Medical OncologyAssociate Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GASeth Wander, MD, PhDDirector, Precision Medicine, Termeer Center for Targeted TherapiesDirector, Translational Research, Breast Oncology ProgramAssistant Professor of Medicine, Harvard Medical SchoolMassachusetts General HospitalBoston, MASponsored by Lilly